News AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 04:00:02 2024-05-20 pm EDT			5-day change	1st Jan Change
164.6 ^USD	-1.12%		+2.03%	+6.19%

May. 17	Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	MT
May. 17	ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week	May. 20	AQ
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	May. 17	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	May. 17
Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	May. 15
Medincell: share price falls after disappointing clinical study	May. 15	CF
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders	May. 13	MT
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders	May. 13	PR
Medincell: share price rises on resumption of trading	May. 09	CF
AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine	May. 08	MT
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	May. 08	MT
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults	May. 08	AQ
Health Canada Approves QULIPTA for the Preventive Treatment of Chronic Migraine in Adults	May. 08	CI
Medincell: listing suspended pending a press release	May. 08	CF
AbbVie to Present at the Bank of America Securities Healthcare Conference	May. 06	PR
AbbVie : Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany	Apr. 30	PU
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30	MT
Health Care Up on Growth Optimism -- Health Care Roundup	Apr. 29	DJ
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	Apr. 29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	Apr. 29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	Apr. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AbbVie Inc.

Equities

ABBV

US00287Y1091

Summary

Filters